363 related articles for article (PubMed ID: 8260357)
1. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
3. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
4. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
Ono K; Komuro C; Tsutsui K; Shibamoto Y; Nishidai T; Takahashi M; Abe M; Shrieve DC
Br J Cancer; 1986 Nov; 54(5):749-54. PubMed ID: 3801271
[TBL] [Abstract][Full Text] [Related]
6. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan.
Russo A; Tochner Z; Phillips T; Carmichael J; DeGraff W; Friedman N; Fisher J; Mitchell JB
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1187-9. PubMed ID: 3744938
[TBL] [Abstract][Full Text] [Related]
7. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
Lee FY; Allalunis-Turner MJ; Siemann DW
Br J Cancer; 1987 Jul; 56(1):33-8. PubMed ID: 3620316
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
[TBL] [Abstract][Full Text] [Related]
12. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
13. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.
Skapek SX; VanDellen AF; McMahon DP; Postels DG; Griffith OW; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1991; 28(1):15-21. PubMed ID: 2040029
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
15. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
16. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Dorr RT; Liddil JD; Soble MJ
Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the protective effect of cyclophosphamide by pre-treatment with buthionine sulfoximine.
Carmichael J; Friedman N; Tochner Z; Adams DJ; Wolf CR; Mitchell JB; Russo A
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1191-3. PubMed ID: 3744939
[TBL] [Abstract][Full Text] [Related]
19. Depletion of tumour glutathione in vivo by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth.
Terradez P; Asensi M; Lasso de la Vega MC; Puertes IR; Viña J; Estrela JM
Biochem J; 1993 Jun; 292 ( Pt 2)(Pt 2):477-83. PubMed ID: 8503882
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
